SeaStar Medical (NASDAQ:ICU) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of SeaStar Medical (NASDAQ:ICU) from a sell rating to a hold rating in a report issued on Saturday morning.

Several other brokerages have also recently issued reports on ICU. Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a research note on Friday, July 17th. Maxim Group set a $8.00 target price on shares of SeaStar Medical and gave the stock a “buy” rating in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, SeaStar Medical presently has an average rating of “Hold” and a consensus target price of $8.00.

SeaStar Medical Trading Up 2.2%

Shares of NASDAQ ICU opened at $3.25 on Friday. The stock has a market cap of $14.33 million, a P/E ratio of -0.83 and a beta of -1.05. SeaStar Medical has a 12-month low of $2.07 and a 12-month high of $12.50. The business’s fifty day simple moving average is $3.67 and its 200-day simple moving average is $3.42.

SeaStar Medical (NASDAQ:ICU) last released its earnings results on Wednesday, August 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.06. SeaStar Medical had a negative return on equity of 162.75% and a negative net margin of 795.51%.The firm had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.49 million. On average, equities analysts forecast that SeaStar Medical will post -3.58 EPS for the current fiscal year.

Hedge Funds Weigh In On SeaStar Medical

Several large investors have recently bought and sold shares of the business. XTX Topco Ltd raised its stake in SeaStar Medical by 395.4% in the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after buying an additional 48,674 shares in the last quarter. Millennium Management LLC purchased a new stake in SeaStar Medical during the 3rd quarter worth about $102,000. Finally, Jane Street Group LLC acquired a new position in shares of SeaStar Medical during the 4th quarter worth about $30,000. Hedge funds and other institutional investors own 1.69% of the company’s stock.

SeaStar Medical Company Profile

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.